Investor Presentation (Nov ‘22)
If you’re interested in learning more about ALRT you can view or download our latest investor presentation here, you can also find all of the company’s press releases below. Please feel free to contact IR for all other inquiries.
Get our investor package
Please enter your information to receive our corporate presentation and an introductory message from our IR department.
ALR Technologies Announces Canadian Launch Plans for the GluCurve Pet CGM
ALR Technologies Inc. announces plans to launch the GluCurve Pet CGM in Canada during Q3 2023 with a direct to veterinarian clinic sales model through https://GluCurve.ca
ALR Technologies Announces Second Generation GluCurve Pet CGM for Diabetic Cats and Dogs
ALR Technologies Inc. announces the issuance of a purchase order for the first shipment of second generation CGM hardware used in the GluCurve Pet CGM
ALR Technologies Announces Sales Guidance for Q4 2022, Q1 2023, and Completion of the GluCurve Pet CGM Manufacturing Agreement
ALR Technologies Inc. announced the completion of a long-term manufacturing and supply agreement with Infinovo Medical Co. Ltd (“Infinovo”) for the Continuous Glucose Monitor (CGM) hardware used in the GluCurve Pet CGM
ALR Technologies is a data management company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes: an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices; a patent pending Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data.
In addition, the animal health division has identified an unmet need in diabetes care and has developed a solution to assist veterinarians in determining the effectiveness of insulin and helping to identify the appropriate dose and frequency of administration for companion animals. Thus, delivering the same optimization of diabetic drug therapies to pets as to humans.